Joel Greenblatt’s Blueprint Medicines BPMC Stock Holding History

Joel Greenblatt’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,545	Closed	-$309K	–	1559
2024 Q4	$309K	Buy	+3,545	New	+$325K	﹤0.01%	1254
2022 Q3	–	Sell	-5,694	Closed	-$288K	–	1179
2022 Q2	$288K	Buy	+5,694	New	+$334K	0.01%	952
2021 Q3	–	Sell	-15,324	Closed	-$1.35M	–	1029
2021 Q2	$1.35M	Buy	15,324 +7,794	+104%	+$714K	0.06%	412
2021 Q1	$732K	Buy	7,530 +3,719	+98%	+$371K	0.03%	575
2020 Q4	$427K	Buy	+3,811	New	+$402K	0.01%	743
2019 Q3	–	Sell	-2,631	Closed	-$248K	–	1095
2019 Q2	$248K	Buy	+2,631	New	+$217K	﹤0.01%	1003
2017 Q2	–	Sell	-25,305	Closed	-$1.01M	–	972
2017 Q1	$1.01M	Buy	+25,305	New	+$906K	0.01%	665
2016 Q4	–	Sell	-8,656	Closed	-$257K	–	950
2016 Q3	$257K	Buy	+8,656	New	+$215K	﹤0.01%	814

Other funds holding BPMC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Joel Greenblatt's BPMC Position: Q1 2025 in Review

Joel Greenblatt sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 3,545 shares — an estimated $309K sold.

Joel Greenblatt first reported a position in BPMC in Q3 2016 and held it in 8 quarters. The position peaked at $1.35M in Q2 2021. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

Joel Greenblatt reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
Joel Greenblatt sold 3,545 Blueprint Medicines shares in Q1 2025, an estimated $309K.
Joel Greenblatt first reported a position in Blueprint Medicines in Q3 2016 and held it in 8 quarters.
Joel Greenblatt's Blueprint Medicines position peaked at $1.35M in Q2 2021.
352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Gotham Asset Management's 13F filing for Q1 2025, filed 15 May 2025.